BR112022020924A2 - Métodos de tratamento de um transtorno do sono, a sonolência diurna em um indivíduo, a insônia, e, daridorexante na forma de sal livre ou farmaceuticamente aceitável - Google Patents
Métodos de tratamento de um transtorno do sono, a sonolência diurna em um indivíduo, a insônia, e, daridorexante na forma de sal livre ou farmaceuticamente aceitávelInfo
- Publication number
- BR112022020924A2 BR112022020924A2 BR112022020924A BR112022020924A BR112022020924A2 BR 112022020924 A2 BR112022020924 A2 BR 112022020924A2 BR 112022020924 A BR112022020924 A BR 112022020924A BR 112022020924 A BR112022020924 A BR 112022020924A BR 112022020924 A2 BR112022020924 A2 BR 112022020924A2
- Authority
- BR
- Brazil
- Prior art keywords
- daytime
- insomnia
- pharmaceutically acceptable
- acceptable salt
- sleep disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2020060940 | 2020-04-19 | ||
| PCT/EP2021/059943 WO2021213923A1 (en) | 2020-04-19 | 2021-04-16 | Medical use of daridorexant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020924A2 true BR112022020924A2 (pt) | 2023-02-14 |
Family
ID=75478068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020924A BR112022020924A2 (pt) | 2020-04-19 | 2021-04-16 | Métodos de tratamento de um transtorno do sono, a sonolência diurna em um indivíduo, a insônia, e, daridorexante na forma de sal livre ou farmaceuticamente aceitável |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230134935A1 (https=) |
| EP (1) | EP4138822A1 (https=) |
| JP (1) | JP7822954B2 (https=) |
| KR (1) | KR20230004670A (https=) |
| CN (1) | CN115427037A (https=) |
| AU (1) | AU2021260018A1 (https=) |
| BR (1) | BR112022020924A2 (https=) |
| CA (1) | CA3175369A1 (https=) |
| CL (1) | CL2022002855A1 (https=) |
| IL (1) | IL297234A (https=) |
| MX (1) | MX2022011179A (https=) |
| PH (1) | PH12022552763A1 (https=) |
| TW (1) | TW202200133A (https=) |
| WO (1) | WO2021213923A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115925699B (zh) * | 2022-02-25 | 2023-10-03 | 南京知和医药科技有限公司 | 具有镇痛活性的稠环化合物及其制备方法与用途 |
| WO2024019978A2 (en) * | 2022-07-19 | 2024-01-25 | Rutgers, The State University Of New Jersey | Therapeutic combinations and methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013502447A (ja) * | 2009-08-24 | 2013-01-24 | グラクソ グループ リミテッド | 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体 |
| ES2617863T3 (es) | 2012-06-04 | 2017-06-20 | Actelion Pharmaceuticals Ltd. | Derivados de bencimidazol-prolina |
| MY179862A (en) | 2013-12-03 | 2020-11-18 | Idorsia Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| SI3077391T1 (sl) | 2013-12-04 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Uporaba benzimidazol-prolinskih derivatov |
| ES2843952T3 (es) | 2014-10-23 | 2021-07-21 | Eisai R&D Man Co Ltd | Composiciones para tratar el insomnio |
| LT3619199T (lt) | 2017-05-03 | 2021-09-27 | Idorsia Pharmaceuticals Ltd | 2-([1,2,3]triazol-2-il)-benzenkarboksirūgšties darinių gamyba |
-
2021
- 2021-04-16 EP EP21718142.9A patent/EP4138822A1/en active Pending
- 2021-04-16 WO PCT/EP2021/059943 patent/WO2021213923A1/en not_active Ceased
- 2021-04-16 IL IL297234A patent/IL297234A/en unknown
- 2021-04-16 PH PH1/2022/552763A patent/PH12022552763A1/en unknown
- 2021-04-16 BR BR112022020924A patent/BR112022020924A2/pt not_active Application Discontinuation
- 2021-04-16 KR KR1020227040124A patent/KR20230004670A/ko active Pending
- 2021-04-16 AU AU2021260018A patent/AU2021260018A1/en active Pending
- 2021-04-16 US US17/996,499 patent/US20230134935A1/en active Pending
- 2021-04-16 CN CN202180028992.7A patent/CN115427037A/zh active Pending
- 2021-04-16 JP JP2022563036A patent/JP7822954B2/ja active Active
- 2021-04-16 CA CA3175369A patent/CA3175369A1/en active Pending
- 2021-04-16 MX MX2022011179A patent/MX2022011179A/es unknown
- 2021-04-19 TW TW110113975A patent/TW202200133A/zh unknown
-
2022
- 2022-10-17 CL CL2022002855A patent/CL2022002855A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3175369A1 (en) | 2021-10-28 |
| TW202200133A (zh) | 2022-01-01 |
| JP2023521492A (ja) | 2023-05-24 |
| AU2021260018A1 (en) | 2022-12-22 |
| MX2022011179A (es) | 2022-10-07 |
| WO2021213923A1 (en) | 2021-10-28 |
| KR20230004670A (ko) | 2023-01-06 |
| JP7822954B2 (ja) | 2026-03-03 |
| IL297234A (en) | 2022-12-01 |
| US20230134935A1 (en) | 2023-05-04 |
| EP4138822A1 (en) | 2023-03-01 |
| CL2022002855A1 (es) | 2023-06-02 |
| CN115427037A (zh) | 2022-12-02 |
| PH12022552763A1 (en) | 2024-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006985A (es) | Metodos para el tratamiento de la depresión. | |
| BR112022000231A2 (pt) | Novos métodos | |
| BR112015023725A2 (pt) | composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filme | |
| BR112015018438A2 (pt) | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento | |
| BR112013031032A2 (pt) | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos | |
| BR112022020924A2 (pt) | Métodos de tratamento de um transtorno do sono, a sonolência diurna em um indivíduo, a insônia, e, daridorexante na forma de sal livre ou farmaceuticamente aceitável | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| MX2011009751A (es) | Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2. | |
| TN2019000019A1 (en) | Treatment and prevention of sleep disorders | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| BR112017007144A2 (pt) | ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição. | |
| BR112015022907A8 (pt) | formas cristalinas de sal de (2-(2-(4-fluorfenil) tiazol-4-il) propan-2-il) carbamato de (s)-quinuclidin-3-ila e seus usos | |
| CO2020009715A2 (es) | Oligonucleótidos antisentido que actúan sobre alfa-sinucleína, y usos de estos | |
| BR112015018360A2 (pt) | terapia de combinação para o tratamento de pneumonia nosocomial | |
| NI201500150A (es) | TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| EP4285993A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| CO2020008425A2 (es) | Oligonucleótidos antisentido que actúan sobre alfa-sinucleína, y usos de estos | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| WO2014165713A3 (en) | Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity | |
| CL2021000743A1 (es) | Métodos para tratar trastornos mieloproliferativos | |
| BR112015022084A2 (pt) | composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol | |
| CO2023017186A2 (es) | Formas cristalinas de trofinetida | |
| BR112019008241A2 (pt) | tratamento do prurigo nodular | |
| BR112018073688A2 (pt) | método de tratamento de hiperglicemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |